Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials
Multiple myeloma (MM) is one of the most common hematological malignancies. It newly affects approximately 21,500 patients (pts) each year in Europe with 15,000 dying from this disease annually [1]. Although, the currently used first-line therapies induce remissions in the majority of pts, relapses are expected to occur in almost all.
Source: Leukemia Research - Category: Hematology Authors: Wolfgang Knauf, Ali Aldaoud, Christoph Losem, Johann Mittermueller, Michael Neise, Beate Niemeier, Johanna Harde, Tanja Trarbach, Karin Potthoff Tags: Research paper Source Type: research
More News: Cancer & Oncology | Clinical Trials | Dexamethasone | Hematology | Leukemia | Myeloma | Revlimid | Study